Novartis Appoints Specialty Drug Division Head To Lead North American Pharma Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Ludwig Hantson becomes head of the North American pharma business and CEO of Novartis Pharmaceuticals immediately, replacing Alex Gorsky.
You may also be interested in...
Novartis To Acquire Majority Stake In Alcon
Deal offers synergies with firm’s Ciba Vision affiliate and ex-U.S. marketing rights to Lucentis.
Drug Development Chief Departs Beleaguered Novartis
Trevor Mundel is set to replace James Shannon, Novartis confirms to “The Pink Sheet” DAILY.
Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says
DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.